Future Fund LLC Sells 4,459 Shares of Guardant Health, Inc. $GH

Posted by Brenda Bartman on May 30th, 2026

Future Fund LLC reduced its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 10.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,827 shares of the company’s stock after selling 4,459 shares during the period. Guardant Health accounts for about 1.3% of Future Fund LLC’s holdings, making the stock its 13th biggest position. Future Fund LLC’s holdings in Guardant Health were worth $3,762,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Guardant Health by 2.1% during the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after purchasing an additional 251,939 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after purchasing an additional 277,001 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Guardant Health by 26.1% during the third quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after purchasing an additional 606,368 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Guardant Health during the third quarter valued at about $114,421,000. Finally, Erste Asset Management GmbH lifted its position in shares of Guardant Health by 10.4% during the third quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after purchasing an additional 66,617 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GH. Evercore set a $110.00 price target on shares of Guardant Health in a research report on Friday, February 20th. Raymond James Financial restated an “outperform” rating and set a $129.00 price objective on shares of Guardant Health in a report on Monday, February 23rd. Canaccord Genuity Group raised their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, February 20th. UBS Group restated a “buy” rating and set a $175.00 price objective on shares of Guardant Health in a report on Friday, January 30th. Finally, Guggenheim downgraded shares of Guardant Health from a “buy” rating to a “buy” rating in a report on Thursday. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $129.79.

Read Our Latest Analysis on Guardant Health

Guardant Health Stock Performance

NASDAQ GH opened at $129.69 on Friday. Guardant Health, Inc. has a 52-week low of $38.03 and a 52-week high of $133.97. The company has a 50-day simple moving average of $95.08 and a 200 day simple moving average of $99.94. The company has a market capitalization of $17.20 billion, a PE ratio of -38.26 and a beta of 1.48.

Insider Transactions at Guardant Health

In other news, Director Ian T. Clark sold 6,876 shares of Guardant Health stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $106.90, for a total value of $735,044.40. Following the completion of the transaction, the director owned 2,975 shares in the company, valued at $318,027.50. This trade represents a 69.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terilyn J. Monroe sold 3,832 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $92.68, for a total transaction of $355,149.76. Following the completion of the transaction, the insider owned 20,990 shares of the company’s stock, valued at $1,945,353.20. This trade represents a 15.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 332,244 shares of company stock valued at $36,156,026. 5.60% of the stock is currently owned by insiders.

Guardant Health Company Profile

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.